CTOs on the Move

Pharvaris

www.pharvaris.com

 
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.pharvaris.com
  • 1 Cranberry Hill Suite 300
    Lexington, MA USA 02421
  • Phone: 212.845.4262

Executives

Name Title Contact Details
Stefan Abele
 Chief Technical Operations Officer Profile

Similar Companies

BioMed Supply

BioMed Supply, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Athira

At Athira, we aim to restore neuronal health for those suffering from neurological diseases, including Alzheimer`s, so that patients can regain their memories, lives, and family relationships. We are a motivated, impassioned team committed to making a positive impact on human health.

Genactis

Genactis is a Fort Washington, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hercules Pharmaceuticals

Silence Therapeutics

Our 20-plus years of RNAi experience together with our validated mRNAi GOLD™ platform make us a partner of choice for pharmaceutical companies looking to access the benefits of the siRNA and add this revolutionary modality to their discovery pipeline. As pioneers in the design and development of siRNAs (short interfering RNAs), Silence Therapeutics is advancing a new generation of medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value. We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the opportunity to address a wide range of conditions in virtually any therapeutic area.